15 Best Dividend Stocks for Lifelong Passive Income
https://www.fool.com/investing/2024/09/30/15-best-dividend-stocks-for-lifelong-passive-incom/?source=iedfolrf0000001
Sep 30, 2024 - These 15 dividend stocks can deliver stable passive income for life.
0
Is Johnson & Johnson the Best Dividend Stock for You?
https://www.fool.com/investing/2024/09/01/is-johnson-johnson-the-best-dividend-stock-for-you/?source=iedfolrf0000001
Sep 01, 2024 - You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors.
0
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
https://www.zacks.com/stock/news/2329915/jnj-seeks-first-fda-nod-for-autoimmune-disease-drug-nipocalimab?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2329915
Aug 30, 2024 - The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
0
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
https://www.zacks.com/stock/news/2329707/pharma-stock-roundup-lly-offers-cheap-zepbound-eu-okays-some-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2329707
Aug 30, 2024 - LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
0
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
https://www.zacks.com/stock/news/2328493/j-j-s-rybrevant-receives-eu-approval-for-expanded-use-in-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2328493
Aug 28, 2024 - The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
0
12 Dividend Stocks to Earn Income Every Month
https://www.fool.com/investing/2024/08/28/12-dividend-stocks-to-earn-income-every-month/?source=iedfolrf0000001
Aug 28, 2024 - Get paid a dividend on a monthly basis.
0
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2327949/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2327949
Aug 27, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.
0
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
https://www.zacks.com/stock/news/2327685/merck-stock-worth-watching-on-pah-drug-winrevair-s-approval-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327685
Aug 27, 2024 - MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
0
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
https://www.fool.com/investing/2024/08/27/meet-wall-street-safest-dividend-stock-small-cap/?source=iedfolrf0000001
Aug 27, 2024 - This relative unknown hasn't missed a dividend payment to its shareholders in more than 200 years!
0
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
https://www.zacks.com/stock/news/2326355/pharma-stock-roundup-fda-nod-to-pfe-mrna-new-covid-jabs-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2326355
Aug 23, 2024 - LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
0